In clinical care, CD26/DPP4 inhibitors are most commonly known for their use in patients with type 2 diabetes, where pharmacological inhibition leads to increased endogenous secretion of insulin through inhibition of the de-activation of glucagon-like peptide-1 and gastroinhibitory protein18. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.